title: New clinical advances in immunotherapy for the treatment of solid tumours.
abstract: Advances in understanding the mechanisms of cancer cells for evading the immune system surveillance, including how the immune system modulates the phenotype of tumours, have allowed the development of new therapies that benefit from this complex cellular network to specifically target and destroy cancer cells. Immunotherapy researchers have mainly focused on the discovery of tumour antigens that could confer specificity to immune cells to detect and destroy cancer cells, as well as on the mechanisms leading to an improved activation of effector immune cells. The Food and Drug Administration approval in 2010 of ipilumumab for melanoma treatment and of pembrolizumab in 2014, monoclonal antibodies against T-lymphocyte-associated antigen 4 and programmed cell death 1, respectively, are encouraging examples of how research in this area can successfully translate into clinical use with promising results. Currently, several ongoing clinical trials are in progress testing new anti-cancer therapies based on the enhancement of immune cell activity against tumour antigens. Here we discuss the general concepts related to immunotherapy and the recent application to the treatment of cancer with positive results that support their consideration of clinical application to patients.
authors.affiliation: Departamento de Biología Celular y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Valentina A
authors.initials: VA
authors.lastname: Zavala
authors.forename: Alexis M
authors.initials: AM
authors.lastname: Kalergis
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm
keywords: T-lymphocyte-associated antigen 4; cancer; clinical; immunotherapy; programmed cell death 1; trial
references.citation: J Clin Oncol. 2010 Jul 1;28(19):3167-75
references.pmid: 20516446
references.citation: J Immunol. 2014 Jun 15;192(12):5451-8
references.pmid: 24907378
references.citation: Cancer. 2010 Jan 15;116(2):292-301
references.pmid: 19924797
references.citation: Oncoimmunology. 2012 May 1;1(3):316-325
references.pmid: 22737607
references.citation: Gene Ther. 2003 Feb;10(4):292-303
references.pmid: 12595888
references.citation: Curr Opin Oncol. 2012 Mar;24(2):191-6
references.pmid: 22185938
references.citation: Nature. 2014 Nov 27;515(7528):577-81
references.pmid: 25428507
references.citation: N Engl J Med. 2014 Dec 4;371(23):2189-2199
references.pmid: 25409260
references.citation: Mol Cancer Res. 2008 May;6(5):751-9
references.pmid: 18458053
references.citation: Mol Cancer Ther. 2007 Jul;6(7):2065-72
references.pmid: 17620435
references.citation: Cancer Gene Ther. 2012 Dec;19(12):811-7
references.pmid: 23037806
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3089-94
references.pmid: 16809734
references.citation: Nat Med. 2012 Aug;18(8):1254-61
references.pmid: 22842478
references.citation: Breast Cancer Res Treat. 2005 Mar;90(1):97-104
references.pmid: 15770533
references.citation: Annu Rev Pathol. 2006;1:119-50
references.pmid: 18039110
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: J Transl Med. 2012 Jun 27;10:134
references.pmid: 22738135
references.citation: Nat Med. 1998 Mar;4(3):328-32
references.pmid: 9500607
references.citation: Ann Surg Oncol. 2006 Aug;13(8):1085-98
references.pmid: 16865596
references.citation: Eur J Immunol. 1994 Dec;24(12):3216-21
references.pmid: 7805750
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1757-61
references.pmid: 17363529
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2046-54
references.pmid: 22547592
references.citation: Folia Histochem Cytobiol. 2005;43(4):213-6
references.pmid: 16382887
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5763-71
references.pmid: 19884534
references.citation: Clin Cancer Res. 2013 Jan 15;19(2):462-8
references.pmid: 23169436
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Front Physiol. 2012 Jul 13;3:270
references.pmid: 22969725
references.citation: J Korean Soc Coloproctol. 2012 Aug;28(4):205-12
references.pmid: 22993707
references.citation: Cancer Immunol Immunother. 2004 Mar;53(3):187-95
references.pmid: 14758508
references.citation: J Clin Oncol. 2011 Dec 1;29(34):4491-7
references.pmid: 22042958
references.citation: Cancer Biother Radiopharm. 2012 Aug;27(6):337-43
references.pmid: 22804456
references.citation: Nature. 2014 Nov 27;515(7528):572-6
references.pmid: 25428506
references.citation: Arch Dis Child. 1978 May;53(5):366-74
references.pmid: 78685
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: Cancer Immunol Immunother. 2013 Feb;62(2):285-97
references.pmid: 22903385
references.citation: Ann Surg Oncol. 2010 Mar;17(3):718-30
references.pmid: 19915919
references.citation: Lancet. 2014 Sep 20;384(9948):1109-17
references.pmid: 25034862
references.citation: Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9
references.pmid: 15569934
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: J Immunotoxicol. 2012 Jul-Sep;9(3):248-58
references.pmid: 22734880
references.citation: Future Oncol. 2014 May;10(6):937-48
references.pmid: 24941980
references.citation: Eur J Immunol. 2012 Jul;42(7):1778-84
references.pmid: 22585706
references.citation: PLoS One. 2012;7(5):e37225
references.pmid: 22615945
references.citation: Cancer Res. 2012 Apr 1;72(7):1672-82
references.pmid: 22318866
references.citation: Prostate. 2001 May 15;47(3):222-9
references.pmid: 11351352
references.citation: Cancer Cell. 2012 Mar 20;21(3):309-22
references.pmid: 22439926
references.citation: Cancer. 2012 May 15;118(10):2594-602
references.pmid: 21989902
references.citation: Melanoma Res. 2009 Oct;19(5):333-4
references.pmid: 19512947
references.citation: J Clin Oncol. 2014 Apr 1;32(10):1020-30
references.pmid: 24590637
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4652-4
references.pmid: 17671159
references.citation: Cancer Res. 2001 Jun 15;61(12):4744-9
references.pmid: 11406546
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5323-37
references.pmid: 19723653
references.citation: Melanoma Res. 2010 Jun;20(3):218-26
references.pmid: 20354459
references.citation: Genes Dev. 2011 Dec 15;25(24):2559-72
references.pmid: 22190457
references.citation: Cancer Immunol Immunother. 2011 Mar;60(3):319-26
references.pmid: 21267721
references.citation: J Clin Invest. 2011 Jun;121(6):2350-60
references.pmid: 21555851
references.citation: Eur Radiol. 2011 Nov;21(11):2344-53
references.pmid: 21681574
references.citation: Nat Rev Cancer. 2009 Jul;9(7):463-75
references.pmid: 19536107
references.citation: Future Oncol. 2010 Jun;6(6):941-9
references.pmid: 20528232
references.citation: Cancer Discov. 2011 Jun;1(1):54-67
references.pmid: 22039576
references.citation: J Clin Invest. 2007 Nov;117(11):3383-92
references.pmid: 17932562
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1099-105
references.pmid: 20100959
references.citation: Nature. 2014 Nov 27;515(7528):563-7
references.pmid: 25428504
references.citation: Adv Immunol. 2004;82:249-93
references.pmid: 14975259
references.citation: Urology. 2013 Aug;82(2):410-5
references.pmid: 23896100
references.citation: Mol Biotechnol. 2008 Oct;40(2):151-60
references.pmid: 18543130
references.citation: N Engl J Med. 2012 Jun 7;366(23):2207-14
references.pmid: 22646510
references.citation: Lancet Oncol. 2013 May;14(6):461-71
references.pmid: 23602601
references.citation: Immunity. 2004 Aug;21(2):137-48
references.pmid: 15308095
references.citation: Br J Cancer. 2012 Aug 21;107(5):864-73
references.pmid: 22878371
references.citation: Nat Rev Urol. 2010 May;7(5):245-57
references.pmid: 20448658
references.citation: J Exp Med. 2010 Sep 27;207(10):2175-86
references.pmid: 20819923
references.citation: Ann Oncol. 2013 Feb;24(2):420-428
references.pmid: 23028040
references.citation: J Oncol Pharm Pract. 2015 Dec;21(6):451-67
references.pmid: 24917416
references.citation: J Clin Oncol. 2015 May 1;33(13):1430-7
references.pmid: 25452452
references.citation: BMC Immunol. 2010 Apr 12;11:19
references.pmid: 20385003
references.citation: J Clin Oncol. 2013 Jul 1;31(19):2388-95
references.pmid: 23715562
references.citation: Cancer Res. 2012 Oct 15;72(20):5151-7; discussion 5158
references.pmid: 22952221
references.citation: Pol Przegl Chir. 2014 Feb;86(2):94-6
references.pmid: 24670341
references.citation: Ann Oncol. 2014 Nov;25(11):2178-2184
references.pmid: 25193987
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7412-20
references.pmid: 19934295
references.citation: Ann Oncol. 2013 Jan;24(1):75-83
references.pmid: 22858559
references.citation: Ann Surg Oncol. 2010 Apr;17(4):1187-93
references.pmid: 20033323
references.citation: Cancer Res. 2009 Dec 15;69(24):9330-6
references.pmid: 19934333
references.citation: J Immunother. 2009 Apr;32(3):322-4
references.pmid: 19242368
references.citation: Curr Pathobiol Rep. 2013 Mar;1(1):37-42
references.pmid: 23420038
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: PLoS One. 2013;8(1):e53745
references.pmid: 23341990
references.citation: Nature. 2010 Sep 30;467(7315):596-9
references.pmid: 20823850
references.citation: Immunol Rev. 2010 Jul;236:219-42
references.pmid: 20636820
references.citation: Can J Surg. 2004 Oct;47(5):347-51
references.pmid: 15540687
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Lancet Oncol. 2011 Nov;12(12):1125-33
references.pmid: 22019520
references.citation: Cancer Res. 2012 Feb 15;72(4):917-27
references.pmid: 22186141
references.citation: N Engl J Med. 2011 Jun 30;364(26):2517-26
references.pmid: 21639810
references.citation: J Cell Physiol. 2012 Feb;227(2):658-67
references.pmid: 21465472
references.citation: Med Oncol. 2012 Dec;29(5):3440-8
references.pmid: 22843292
references.citation: Oncol Rep. 2012 Oct;28(4):1131-8
references.pmid: 22895835
references.citation: N Engl J Med. 2012 Nov 8;367(19):1783-91
references.pmid: 23020162
references.citation: Cancer. 2014 Mar 1;120(5):642-51
references.pmid: 24222194
references.citation: Cancer Immunol Immunother. 2014 May;63(5):437-48
references.pmid: 24531387
references.citation: Eur J Cancer. 2008 Jul;44(10):1345-89
references.pmid: 18280139
references.citation: Nature. 2014 Nov 27;515(7528):558-62
references.pmid: 25428503
references.citation: Exp Ther Med. 2012 Aug;4(2):243-248
references.pmid: 22970029
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: Mediators Inflamm. 2012;2012:690643
references.pmid: 22851815
references.citation: Lancet Oncol. 2014 Jan;15(1):59-68
references.pmid: 24331154
references.citation: Cancer Res. 2006 Apr 1;66(7):3381-5
references.pmid: 16585157
references.citation: J Immunother. 2014 Jul-Aug;37(6):348-50
references.pmid: 24911795
references.citation: J Clin Oncol. 2014 May 10;32(14):1437-44
references.pmid: 24733796
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801
references.pmid: 21825174
references.citation: J Exp Med. 2010 Sep 27;207(10):2187-94
references.pmid: 20819927
references.citation: Adv Cancer Res. 2006;95:1-30
references.pmid: 16860654
references.citation: Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41
references.pmid: 21873242
references.citation: J Transl Med. 2013 Mar 03;11:54
references.pmid: 23452415
references.citation: Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
references.pmid: 20385810
references.citation: Clin Cancer Res. 2012 Oct 1;18(19):5460-70
references.pmid: 22896657
references.citation: Transl Oncol. 2013 Jun 01;6(3):282-9
references.pmid: 23730407
references.citation: Clin Cancer Res. 2011 Jun 1;17(11):3520-6
references.pmid: 21471425
references.citation: Dermatology. 2013;227(2):146-9
references.pmid: 24051549
references.citation: N Engl J Med. 2013 Jul 11;369(2):134-44
references.pmid: 23724846
references.citation: Clin Cancer Res. 2013 Oct 1;19(19):5300-9
references.pmid: 24089443